J. Goldman & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

J. Goldman & Co’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$7.72M	–	845
2025 Q4	$7.72M	Buy	10,000 +2,000	+25%	+$1.36M	0.2%	141
2025 Q3	$4.5M	Sell	8,000 -8,000	-50%	-$4.52M	0.11%	209
2025 Q2	$8.4M	Buy	+16,000	New	+$8.93M	0.2%	148
2025 Q1	–	Sell	-6,000	Closed	-$4.27M	–	603
2024 Q4	$4.27M	Buy	+6,000	New	+$5.04M	0.11%	206
2024 Q1	–	Sell	-5,400	Closed	-$4.74M	–	505
2023 Q4	$4.74M	Sell	5,400 -26,400	-83%	-$21.7M	0.19%	131
2023 Q3	$26.2M	Buy	31,800 +14,200	+81%	+$11.2M	0.92%	30
2023 Q2	$12.6M	Buy	+17,600	New	+$13.6M	0.46%	70
2022 Q4	–	Sell	-13,000	Closed	-$8.96M	–	469
2022 Q3	$8.96M	Buy	+13,000	New	+$8.18M	0.43%	75

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

J. Goldman & Co's REGN Position: Q1 2026 in Review

J. Goldman & Co increased its Regeneron Pharmaceuticals (REGN) stake by 156% in Q1 2026, buying an estimated $7.59M and bringing the position to 16,268 shares worth $12.6M. The position accounts for 0.37% of the portfolio, ranked #79.

J. Goldman & Co first reported a position in REGN in Q2 2022 and has held it in 16 quarters since. The position peaked at $40.1M in Q4 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

J. Goldman & Co held 16,268 shares of Regeneron Pharmaceuticals worth $12.6M as of Q1 2026.
J. Goldman & Co bought 9,916 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $7.59M.
Regeneron Pharmaceuticals made up 0.37% of J. Goldman & Co's portfolio in Q1 2026, its #79 holding.
J. Goldman & Co first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
J. Goldman & Co's Regeneron Pharmaceuticals position peaked at $40.1M in Q4 2023.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.